Foam in anterior saphenous vein (FISA-Study)

Foam in anterior saphenous vein (FISA-Study) - FISA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036600

Enrollment

189

Registered

2026-03-03

Start date

2026-01-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I83

Interventions

Group 1: Foam Sclerotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Insufficiency of VSA

Exclusion criteria

Exclusion criteria: Contraindications for sclerotherapy

Design outcomes

Primary

Measure	Time frame
Occlusion Rate of VSA 12 months after sclerotherapy	—

Secondary

Measure	Time frame
Contentment, life-qualitis, pain and adverse events within 12 months after sclerotherapy	—

Countries

Germany

Contacts

Public ContactBirgit Kahle

Klinik für Dermatologie, Universitätsklinikum Schleswig-Holstein

ambulanz.hautklinik.luebeck@uksh.de0415 500 41550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026